Your browser doesn't support javascript.
loading
Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor.
Cai, Yu; He, Jianlin; Wu, Zhipeng; He, Weigang; Dai, Xiaoming; Xu, Yan; Cheng, Min; Yang, Na; Ren, Yongxin; Wang, Guanglin; Wang, Jian; Sai, Yang; Jia, Hong; Dai, Guangxiu; Li, Xiong; Su, Weiguo.
Afiliación
  • Cai Y; HUTCHMED Limited, Shanghai, China yuc@hutch-med.com.
  • He J; HUTCHMED Limited, Shanghai, China.
  • Wu Z; HUTCHMED Limited, Shanghai, China.
  • He W; HUTCHMED Limited, Shanghai, China.
  • Dai X; HUTCHMED Limited, Shanghai, China.
  • Xu Y; HUTCHMED Limited, Shanghai, China.
  • Cheng M; HUTCHMED Limited, Shanghai, China.
  • Yang N; HUTCHMED Limited, Shanghai, China.
  • Ren Y; HUTCHMED Limited, Shanghai, China.
  • Wang G; HUTCHMED Limited, Shanghai, China.
  • Wang J; HUTCHMED Limited, Shanghai, China.
  • Sai Y; HUTCHMED Limited, Shanghai, China.
  • Jia H; HUTCHMED Limited, Shanghai, China.
  • Dai G; HUTCHMED Limited, Shanghai, China.
  • Li X; HUTCHMED Limited, Shanghai, China.
  • Su W; HUTCHMED Limited, Shanghai, China.
J Pharmacol Exp Ther ; 388(1): 156-170, 2024 01 02.
Article en En | MEDLINE | ID: mdl-37918855
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Neoplasias Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades Autoinmunes / Neoplasias Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article